Aspiriant LLC Has $1.82 Million Position in Danaher Co. (DHR)

Aspiriant LLC lessened its position in shares of Danaher Co. (NYSE:DHR) by 10.8% during the first quarter, HoldingsChannel.com reports. The fund owned 13,794 shares of the conglomerate’s stock after selling 1,675 shares during the period. Aspiriant LLC’s holdings in Danaher were worth $1,824,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of DHR. Norges Bank bought a new stake in Danaher during the 4th quarter worth approximately $747,082,000. Oregon Public Employees Retirement Fund increased its holdings in Danaher by 10,085.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,863,048 shares of the conglomerate’s stock worth $67,000 after acquiring an additional 6,795,666 shares during the period. Findlay Park Partners LLP increased its holdings in Danaher by 25.0% during the 4th quarter. Findlay Park Partners LLP now owns 4,595,000 shares of the conglomerate’s stock worth $473,836,000 after acquiring an additional 920,000 shares during the period. 1832 Asset Management L.P. increased its holdings in Danaher by 74.3% during the 4th quarter. 1832 Asset Management L.P. now owns 2,129,142 shares of the conglomerate’s stock worth $219,310,000 after acquiring an additional 907,593 shares during the period. Finally, Polar Capital LLP increased its holdings in Danaher by 678.1% during the 4th quarter. Polar Capital LLP now owns 744,570 shares of the conglomerate’s stock worth $76,780,000 after acquiring an additional 648,885 shares during the period. 76.98% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Walter G. Lohr sold 10,578 shares of the company’s stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $126.85, for a total value of $1,341,819.30. Following the completion of the sale, the director now owns 20,691 shares of the company’s stock, valued at approximately $2,624,653.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Mitchell P. Rales acquired 1,900 shares of the business’s stock in a transaction dated Friday, May 10th. The stock was acquired at an average cost of $130.78 per share, with a total value of $248,482.00. The disclosure for this purchase can be found here. Insiders sold a total of 424,761 shares of company stock valued at $54,983,097 in the last ninety days. 11.40% of the stock is owned by corporate insiders.

A number of brokerages have recently commented on DHR. Zacks Investment Research lowered shares of Danaher from a “hold” rating to a “sell” rating in a report on Tuesday, April 30th. Needham & Company LLC reissued a “buy” rating and issued a $141.00 price target (up previously from $138.00) on shares of Danaher in a report on Wednesday, April 17th. Jefferies Financial Group increased their price target on shares of Danaher to $140.00 and gave the stock a “buy” rating in a report on Tuesday, February 26th. Deutsche Bank increased their price target on shares of Danaher to $130.00 and gave the stock a “buy” rating in a report on Tuesday, February 26th. Finally, UBS Group increased their price target on shares of Danaher from $125.00 to $144.00 and gave the stock a “buy” rating in a report on Tuesday, February 26th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $131.75.

Shares of NYSE:DHR opened at $131.10 on Friday. Danaher Co. has a one year low of $94.59 and a one year high of $134.67. The firm has a market capitalization of $94.70 billion, a PE ratio of 29.00, a P/E/G ratio of 2.56 and a beta of 1.02. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.74 and a current ratio of 2.18.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Thursday, April 18th. The conglomerate reported $1.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.01 by $0.06. Danaher had a net margin of 12.04% and a return on equity of 11.61%. The company had revenue of $4.88 billion during the quarter, compared to analysts’ expectations of $4.80 billion. During the same quarter in the prior year, the company earned $0.99 EPS. The firm’s revenue was up 3.9% on a year-over-year basis. Research analysts expect that Danaher Co. will post 4.77 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Thursday, June 27th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.52%. Danaher’s dividend payout ratio (DPR) is 15.04%.

ILLEGAL ACTIVITY WARNING: “Aspiriant LLC Has $1.82 Million Position in Danaher Co. (DHR)” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.chaffeybreeze.com/2019/05/19/aspiriant-llc-has-1-82-million-position-in-danaher-co-dhr.html.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Further Reading: Are all No-Load Funds Equal?

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.